Generic Risks Still Too High

Discussion in 'Pfizer' started by Anonymous, Sep 5, 2013 at 1:25 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Albeit Pfizer is looking to mitigate the impact of generic competition by bringing to market new products, including treatments for auto-immune disorders, cardiology, and oncology, as demonstrated by Viagra, its portfolio of drugs at-risk of losing market exclusivity is high. Up to 35% of the $23.6 billion in sales derived from branded pharmaceuticals in 1H:13 is either currently battling an onslaught of cheaper alternatives or will soon face generic competition, including several best-selling drugs - See more at: http://ycharts.com/analysis/story/dark_patent_issues_behind_the_pfizer_cash_machine#sthash.i7UwAxoF.dpuf